SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Divis Laboratories reports 9% growth in Q3FY17 net profit

06 Feb 2017 Evaluate

Divis Laboratories has reported results for third quarter ended December 31, 2016. 

The company has reported 8.74% rise in its net profit at Rs 268.32 crore for the quarter under review as compared to Rs 246.76 crore for the same quarter in the previous year. Total income of the company increased by 13.84% at Rs 994.95 crore for the quarter under review as compared to Rs 873.98 crore for the corresponding quarter previous year.

Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.

Divis Lab Share Price

6228.95 -68.55 (-1.09%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×